- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05958368
Évaluation de la valeur des avocats sur le contrôle glycémique dans le diabète de type 2 (AVOCADO-T2D)
Les effets des avocats Hass sur le contrôle glycémique chez les personnes atteintes de diabète de type 2 : un essai croisé contrôlé randomisé
The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70808
- Pennington Biomedical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participant reported diagnosis of Type 2 diabetes
- HbA1c between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL
- BMI 27-50 kg/m2 (inclusive)
- Age range - 18 - 65 years (inclusive)
- On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)
- Willing to follow all requirements of study protocol including blood draws
- Under the care of a physician who will be responsible for managing the subject's diabetes
- Willing to give release to provide their treating MD with information about the trial
Exclusion Criteria:
- Not willing or unable to consume study foods including avocados
- Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months
- Taking prescription or OTC weight loss medications within last 4 weeks
- History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
- History of major surgery within three months of enrollment
- Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)
- Renal insufficiency consisting of potassium over 5.5 (mmol/L) on a non-hemolyzed specimen, or a creatinine over 2.5 mg/dL
- Bilirubin over 3 (mg/dL) or an albumin less than 3 (g/dL)
- ALT > 3 (IU/L) times the upper limit of normal (normal range is 7-56)
- Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.
- Those on higher doses of diuretics (furosemide 40mg or higher or comparable)
- Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)
- Presence of implanted cardiac defibrillator
- Blood pressure ≥180/100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.
- Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable
- Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease
- Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.
- Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)
- Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control
- Currently consuming >14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation
- Participation in another clinical trial within 30 days prior to enrollment
- Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Avocado
Participants will consume 1 Hass avocado a day. |
The Hass Avocado group will consume 7 avocados a week (1 / day; ~240 kcals/d).
Autres noms:
|
|
Comparateur actif: Other Fruit(s)
Participants in the other fruit arm will receive other fruits. |
The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting Blood Glucose
Délai: Week 5 - Week 0
|
the primary outcomes are based on within subject concentration change scores |
Week 5 - Week 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting Insulin
Délai: Week 5 - Week 0
|
within subject concentration change scores |
Week 5 - Week 0
|
|
Fructosamine
Délai: Week 5 - Week 0
|
within subject concentration change scores |
Week 5 - Week 0
|
|
Glycated Albumin
Délai: Week 5 - Week 0
|
within subject concentration change scores |
Week 5 - Week 0
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Blood Glucose
Délai: Week 5 - Week 0
|
Continuous Glucose Monitoring |
Week 5 - Week 0
|
|
Glucose
Délai: Week 5 - Week 0
|
Oral Glucose Tolerance Test (OGTT) |
Week 5 - Week 0
|
|
Insulin
Délai: Week 5 - Week 0
|
Oral Glucose Tolerance Test (OGTT) |
Week 5 - Week 0
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: John W Apolzan, PhD, Pennington Biomedical Research Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Diabète sucré
- Hyperinsulinisme
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- En surpoids
- Obésité
- Diabète sucré, Type 2
- Résistance à l'insuline
Autres numéros d'identification d'étude
- PBRC 2023-033
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Data may be requested. The PI and sponsor will be notified. The proposed research question must be included. All IPD that underlie results in a publication after a DTA with the institution.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .